Shots:

• The P-I trial involves assessing MSB-0221 (ShA9) or vehicle applied topically on forearm skin in 54 adults with staphylococcus aureus-positive AD for 1week
• The expression of mRNA for psmα was inhibited from S. aureus isolated from all participants while the correlation was observed within 7days b/w improvement in local eczema severity and killing of S. aureus
• In general- the results showed the safety and potential benefits of bacteria to treat chronic skin diseases. Additionally- the company plans to conduct a P-II clinical trial that will evaluate MSB-0221 vs PBO in 150 patients over a 12wks. treatment period to treat AD

 ­ Ref: GlobeNewswire | Image: Owler